“…Baseline characteristics of all included studies are listed in Table 1. Underlying malignancies for these trials included RCC [5,16,18,22,24] (five trials), HCC [7,13,17] (three), NSCLC [8][9][10]12] (four), breast cancer [11,14,19] (three), melanoma [6,15] (two), thyroid cancer [21] (one), urothelial cancer [23] (one) and CRC [20] (one); The starting dose and schedule of sorafenib was based on the US Food and Drug Administration guideline (400 mg, orally, twice daily) in each study.…”